REGULATORY

• Japan Wants to Spur Regulatory Use of RWD, but Still Puts Weight on RCTs
  July 10, 2024

• Ex-Health Minister Otsuji to Retire from Politics Next Summer
  July 10, 2024

• PMDA to Push Simultaneous Development of Pediatric Drugs via New Consultation Center
  July 9, 2024

• LDP Group Renews Call for Gender-Neutral HPV Vaccination
  July 9, 2024

• MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
  July 8, 2024

• Breyanzi’s Label Expansion Up for MHLW Panel Review on July 19
  July 8, 2024

• Panelists Wary of Proposed Switch of Generic GMP Inspection Authority to PMDA
  July 8, 2024

• Minister Nudges Generic Product Consolidation, Pitches “5 Makers per API”
  July 5, 2024

• LDP Veteran Seiichi Eto to Bow Out from Politics Next Summer
  July 5, 2024

• Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
  July 4, 2024

• Over 60% of Generic Firms Carry Jointly Developed Products, 98% of Espha Drugs Fall into This Category
  July 3, 2024

• LDP Group Calls for MCI Screening for Early Detection of Alzheimer’s
  July 3, 2024

• New ICH Topic on RWD to Be Proposed towards Its Use in Regulatory Review
  July 2, 2024

• Sato Named MHLW’s Top Pharmacy Officer; Kiyohara to Steer Drug Pricing Reform
  July 2, 2024

• MHLW Shuffles Senior Bureaucrats, Ihara Tapped as Vice Health Minister
  July 2, 2024

• PMDA Kicks Off Consultations for Pediatric and Rare Disease Drugs
  July 2, 2024

• PMDA Opens 1st Overseas Office in Bangkok
  July 2, 2024

• Minister Wants Consensus on Future Generic Industry at Upcoming Confab
  July 1, 2024

• MHLW to Revise Process to Share Info on Nitrosamine Impurities after Guidance Issued
  June 28, 2024

• MHLW Project Team Proposes New Subsidies for Early R&D of Intractable Disease Drugs
  June 28, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• …
• Next ›
• 最終 »